Literature DB >> 16169353

Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention.

Carrie L Selvaraj1, Hitinder S Gurm, Ritesh Gupta, Stephen G Ellis, Deepak L Bhatt.   

Abstract

Previous studies have shown that patients with chronic obstructive pulmonary disease (COPD) who undergo surgical revascularization have higher in-hospital mortality rates. Limited data are available on the outcomes of patients with COPD undergoing percutaneous coronary intervention (PCI). Our study evaluated the association between COPD and in-hospital and long-term mortality in patients undergoing PCI. We studied 10,994 patients who underwent PCI from 1997 to 2003 at our institution (1,117 with and 9,877 without COPD). A patient was considered to have COPD if it was listed as a co-morbid condition in our database. The primary end point was all-cause mortality. Cox logistic regression models were used to determine whether COPD was an independent predictor of all-cause mortality after PCI. The mean age of the study population was 64 years, and 70.2% were men. Significantly more patients with COPD died in hospital (2.9% vs 1.2%, p <0.0001). The median follow-up was 33 months; 89.6% of patients without COPD versus 75.6% of patients with COPD (log-rank 280, degree of freedom 1, p <0.0001) were alive at the end of the follow-up. After adjusting for other variables known to increase mortality, COPD was a significant independent predictor of in-hospital death (odds ratio 2.51, 95% confidence interval 1.45 to 4.35, p = 0.001) and long-term mortality (hazard ratio 2.16, 95% confidence interval 1.81 to 2.56, p <0.0001) after PCI. In conclusion, patients with a history of COPD have higher in-hospital and long-term mortality rates than those without COPD after PCI.

Entities:  

Mesh:

Year:  2005        PMID: 16169353     DOI: 10.1016/j.amjcard.2005.05.016

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.

Authors:  Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; David A Schoenfeld; Deepak L Bhatt; Sami Z Daoud; Beatriz Seoane; Colin Reisner; Esther Garcia Gil
Journal:  Chronic Obstr Pulm Dis       Date:  2018-01-24

2.  The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study.

Authors:  Mihaela S Stefan; Raveendhara R Bannuru; Darleen Lessard; Joel M Gore; Peter K Lindenauer; Robert J Goldberg
Journal:  Chest       Date:  2011-12-29       Impact factor: 9.410

3.  Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry.

Authors:  Jonathan R Enriquez; Shailja V Parikh; Faith Selzer; Alice K Jacobs; Oscar Marroquin; Suresh Mulukutla; Vankeepuram Srinivas; Elizabeth M Holper
Journal:  Chest       Date:  2011-04-28       Impact factor: 9.410

4.  Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.

Authors:  Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; Deepak L Bhatt; Sami Z Daoud; Sofia Zetterstrand; Colin Reisner; Esther Garcia Gil
Journal:  JAMA       Date:  2019-05-07       Impact factor: 56.272

5.  Long-Term Outcomes for Chinese COPD Patients After PCI: A Propensity Score Matched, Double-Cohort Study.

Authors:  Yitian Zheng; Yu Qi; Samuel Seery; Wenyao Wang; Wei Zhao; Tao Shen; Lequn Zhou; Jie Yang; Chen Li; Xuliang Wang; Jun Gao; Xiangbin Meng; Erdan Dong; Yi-Da Tang
Journal:  Front Cardiovasc Med       Date:  2022-06-09

6.  Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal:  Eur J Heart Fail       Date:  2009-01-27       Impact factor: 15.534

7.  Coronary artery disease is under-diagnosed and under-treated in advanced lung disease.

Authors:  Robert M Reed; Michael Eberlein; Reda E Girgis; Salman Hashmi; Aldo Iacono; Steven Jones; Giora Netzer; Steven Scharf
Journal:  Am J Med       Date:  2012-09-06       Impact factor: 4.965

8.  Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study.

Authors:  Rutao Wang; Mariusz Tomaniak; Kuniaki Takahashi; Chao Gao; Hideyuki Kawashima; Hironori Hara; Masafumi Ono; David van Klaveren; Robert-Jan van Geuns; Marie-Claude Morice; Piroze M Davierwala; Michael J Mack; Adam Witkowski; Nick Curzen; Sergio Berti; Francesco Burzotta; Stefan James; Arie Pieter Kappetein; Stuart J Head; Daniel J F M Thuijs; Friedrich W Mohr; David R Holmes; Ling Tao; Yoshinobu Onuma; Patrick W Serruys
Journal:  Clin Res Cardiol       Date:  2021-03-12       Impact factor: 5.460

9.  Coronary artery calcification, epicardial fat burden, and cardiovascular events in chronic obstructive pulmonary disease.

Authors:  Thomas Gaisl; Christian Schlatzer; Esther I Schwarz; Mathias Possner; Julia Stehli; Noriane A Sievi; Christian F Clarenbach; Damini Dey; Piotr J Slomka; Philipp A Kaufmann; Malcolm Kohler
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

10.  Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study.

Authors:  Pere Almagro; Anna Lapuente; Julia Pareja; Sergi Yun; Maria Estela Garcia; Ferrán Padilla; Josep L I Heredia; Alex De la Sierra; Joan B Soriano
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.